Coronavirus – Pfizer C5091018

This is a study to evaluate the efficacy and safety of Ibuzatrelvir for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants.

Inclusion Criteria:

• 18 years of age or older at screening.
• Confirmed SARS-CoV-2 infection as determined by RAT (or other locally approved test) collected within 2 days prior to randomization.
• Severely immunocompromised due to:
  • Solid organ or islet cell transplant recipient who is receiving immunosuppressive therapy;
  • Active hematologic malignancy (eg, chronic lymphocytic lymphoma, non-Hodgkin lymphoma, multiple myeloma, acute leukemia);
  • Receipt of CAR-T-cell therapy or HCT either within 2 years of transplantation or who are receiving immunosuppressive therapy;
  • Currently receiving B-cell depleting therapies (eg, rituximab).
• Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.